[Influence of clozapine on neuroleptigenic extrapyramidal motor disturbances (author's transl)].
1. Human neuroleptogenic EPMS-disturbances are reversed by clozapine in animal experiments and in clinical use. This is consistent with the central anticholinergic efficacy of clozapine. 2. Clozapine seems to be a favourable concomitant medication when high dosage therapy of neuroleptics is applied--or at the incidence of dyskinesia.
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003024:Clozapine / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy; D010919:Placebos
D014150:Antipsychotic Agents; D003984:Dibenzazepines; D010919:Placebos; D003024:Clozapine
Die Beeinflussung neuroleptogener extrapyramidalmotorischer Störungen durch Clozapin.